ANNX רווח נקי למניה ב-12 החודשים האחרונים Annexon Biosciences Inc.

Intellectual property protection via antibody patents creates a high barrier to entry for competitors, providing Annexon, Inc. (ANNX) with strong market power due to its unique method of blocking the C1q protein. The change in rolling net income per share visualizes this correlation, where -1.03 shows the value of this parameter. However, the absence of commercial products necessitates a period of planned capital burn for research.

Annexon, Inc. focuses on developing innovative therapies for neurodegenerative pathologies by blocking the C1q protein to protect neural connections. The current value of -1.03 reflects the net income allocated per share for the year, allowing for an assessment of the business's actual profitability by analyzing the fundamental EPS TTM metric for sustainable growth or the risk of asset overvaluation.